Sermorelin
A GHRH analogue with older clinical and diagnostic history that now appears frequently in the research and wellness peptide market.
Also referenced as: Sermorelin Acetate, Geref
Also appears in: Muscle Growth
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary lane: Growth Hormone. Also surfaces under Muscle Growth for browsing and discovery.
Sermorelin Acetate, Geref
No FDA label signal · 41 trials · 30 PubMed results
What sermorelin is
Sermorelin is a growth hormone-releasing hormone analogue that sits closer to the clinical side of the GH category than many generic secretagogues. It is still common in vendor listings and wellness-adjacent peptide conversations.
Why it matters
It helps bridge the gap between older hormone-therapy language and today’s research-market catalog culture.
Regulatory context
Sermorelin products widely sold through peptide vendors should be understood as unapproved retail-market offerings, not as interchangeable with any prior medical or diagnostic context.
Practical reading note
Sermorelin is a good reminder that a compound can have a more serious historical footing than the average peptide listing while still being marketed in ways that go far beyond that footing.